Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Uterine Cervical Neoplasms 1 Rhabdomyosarcoma, Embryonal 1 Rhabdomyosarcoma, Alveolar 1 Rhabdomyosarcoma 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Hodgkin Disease 1 Carcinoma, Non-Small-Cell Lung 1 Adenocarcinoma 1

Interventions

pembrolizumab 18 Specimen Handling 16 Magnetic Resonance Spectroscopy 11 Biopsy 11 Paclitaxel 8 Carboplatin 8 trastuzumab deruxtecan 6 Pemetrexed 6 Nivolumab 6 Irinotecan 6 Fulvestrant 6 Bevacizumab 6 Radiosurgery 5 Leucovorin 5 Gemcitabine 5 Fluorouracil 5 Cetuximab 5 palbociclib 4 Oxaliplatin 4 Letrozole 4 Cisplatin 4 olaparib 3 durvalumab 3 Taxes 3 Ipilimumab 3 Docetaxel 3 Capecitabine 3 130-nm albumin-bound paclitaxel 3 sacituzumab govitecan 2 ribociclib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × Vinorelbine × 30 days × Clear all

NCT07007559 2026-06-05

ASPEN-09-03

ALX Oncology Inc.

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡